Michael D. Grisham
Oprichter bij Curate Biosciences
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David Backer | M | - |
Curate Biosciences
Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | - |
Daniel Getts | M | - |
Curate Biosciences
Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | 2 jaar |
Mayo Pujols | M | 55 |
Curate Biosciences
Curate Biosciences Miscellaneous Commercial ServicesCommercial Services Curate Biosciences engages in the development of a liquid biopsy platform for obtaining rare circulating tumor cells. It offers a desktop fluidic system for cell separation that pumps blood through a disposable microchip. The company was founded by Michael D. Grisham in 2002 and is headquartered in Richmond, VA. | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Paul Billings | M | 71 |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | 1 jaar |
Susan Siegel | F | 63 |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Ronald G. Tompkins | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Anne R. Kopf-Sill | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Lee Aurich | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Lena Wu | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Lou Dietz | M | - |
Cellective Dx Corp.
Cellective Dx Corp. Pharmaceuticals: GenericHealth Technology Informed decisions will improve the way cancer is treated. On-Q-ity is an innovative diagnostic company that is focused on providing physicians with the tools they need to make the best decision when treating individual cancer patients. Its platform will enable better decision-making across multiple cancers: improving the cost of treatment, the quality of life for patients and ultimately increasing survival. Products currently in development are based on two core technologies: 1) DNA repair biomarkers that predict treatment response and 2) Microfluidic chip technology that enables capture, enumeration and characterization of circulating tumor cells (CTCs) in the bloodstream. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 10 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Michael D. Grisham
- Persoonlijk netwerk